Lyra Therapeutics/LYRA

$0.33

-0.68%
-
1D1W1MYTD1YMAX

About Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

Ticker

LYRA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Maria Palasis

Employees

109

Headquarters

Watertown, United States

LYRA Metrics

BasicAdvanced
$20M
Market cap
-
P/E ratio
-$1.23
EPS
-0.02
Beta
-
Dividend rate
$20M
-0.02429
$6.79
$0.31
3.2M
4.777
-58.52%
-95.93%
-68.02%
12.102
0.262
0.262
28.74%
-9.48%

What the Analysts think about LYRA

Analyst Ratings

Majority rating from 5 analysts.
Hold

Price Targets

Average projection from 2 analysts.
278.79% upside
High $2.00
Low $0.50
$0.33
Current price
$1.25
Average price target

LYRA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-4,480% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
400%
Net income
-$22M
48.34%
Profit margin
-4,480%
-70.33%

LYRA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 33.59%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.27
-$0.22
-$0.35
-
Expected
-$0.42
-$0.32
-$0.32
-$0.26
-$0.33
Surprise
-14.96%
-15.09%
-30.16%
33.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Lyra Therapeutics stock?

Lyra Therapeutics (LYRA) has a market cap of $20M as of May 30, 2024.

What is the P/E ratio for Lyra Therapeutics stock?

The price to earnings (P/E) ratio for Lyra Therapeutics (LYRA) stock is 0 as of May 30, 2024.

Does Lyra Therapeutics stock pay dividends?

No, Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Lyra Therapeutics dividend payment date?

Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Lyra Therapeutics?

Lyra Therapeutics (LYRA) has a beta rating of -0.02. This means that it has an inverse relation to market volatility.

What is the Lyra Therapeutics stock price target?

The target price for Lyra Therapeutics (LYRA) stock is $1.25, which is 278.79% above the current price of $0.33. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Lyra Therapeutics stock

Buy or sell Lyra Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing